III

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022 - 12:00pm

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Global Acute Myeloid Leukaemia Pipeline Landscape Report 2021 - Comprehensive Insights for Approx 150+ Companies and 150+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:58am

This "Acute myeloid leukaemia - Pipeline Insight, 2021" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Acute myeloid leukaemia pipeline landscape.

Key Points: 
  • This "Acute myeloid leukaemia - Pipeline Insight, 2021" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Acute myeloid leukaemia pipeline landscape.
  • "Acute myeloid leukaemia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Acute myeloid leukaemia pipeline landscape is provided which includes the disease overview and Acute myeloid leukaemia treatment guidelines.
  • The assessment part of the report embraces, in depth Acute myeloid leukaemia commercial assessment and clinical assessment of the pipeline products under development.

Global Idiopathic Pulmonary Fibrosis (IPF) Market Pipeline Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:31am

This "Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape.

Key Points: 
  • This "Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021," report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape.
  • "Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Idiopathic Pulmonary Fibrosis pipeline landscape is provided which includes the disease overview and Idiopathic Pulmonary Fibrosis treatment guidelines.
  • Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Global Postmenopausal Osteoporosis Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:23am

The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Postmenopausal Osteoporosis - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Postmenopausal osteoporosis - Pipeline Insight, 2021 report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Postmenopausal osteoporosis pipeline landscape.
  • Blosozumab is a humanised IgG4 monoclonal antibody, being developed by Eli Lilly and Company, for the treatment of postmenopausal osteoporosis.
  • Postmenopausal osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Retrieved on: 
Monday, January 17, 2022 - 11:40am

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.

Key Points: 
  • Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
  • We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board, said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics.
  • Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it, said Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics Board of Directors.
  • Elastrin Therapeutics Scientific Advisory Board is comprised of:
    Prof. Charles O'Neill, MD: Dr. ONeill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022 - 7:00am

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact the Firm Before February 8, 2022

Retrieved on: 
Friday, January 14, 2022 - 11:36pm

Investors have until February 8, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 8, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Revance, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
  • Kirby McInerney LLP is a New York-based plaintiffs law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

NHS Management Continues Investigation of Data Incident

Retrieved on: 
Friday, January 14, 2022 - 10:00pm

In the meantime, NHS has taken the necessary steps to help ensure the security of its data system going forward.

Key Points: 
  • In the meantime, NHS has taken the necessary steps to help ensure the security of its data system going forward.
  • Anyone who desires further information about the data incident can go to the NHS webpage at nhsmanagement.com for more information.
  • NHS Management, LLC ("NHS") is providing notice of a recent event that may affect the security of certain information.On May 16, 2021, NHS discovered that it was the victim of a sophisticated cyberattack.
  • NHS immediately launched an investigation to confirm the full nature and scope of the incident and restore functionality to impacted systems.

VentureSouth Announces Successful Exit From Portfolio Company Atlas Organics

Retrieved on: 
Friday, January 14, 2022 - 5:00pm

VentureSouth first invested in Atlas Organics by leading the company's seed round in late 2015, when Atlas was an early-stage startup with a team of fewer than five people.

Key Points: 
  • VentureSouth first invested in Atlas Organics by leading the company's seed round in late 2015, when Atlas was an early-stage startup with a team of fewer than five people.
  • Including four additional funding rounds over the next six years, approximately 200 VentureSouth members invested nearly $2 million in Atlas Organics as the company grew to over 135 people across five states.
  • Three VentureSouth sidecar funds (VentureSouth Angel Funds I, II, and III) also invested in Atlas.
  • To learn more about VentureSouth, and perhaps be a part of the next Atlas Organics, please visit https://venturesouth.vc .

BitNile Holdings Partners With Ed Carpenter Racing to Sponsor the No. 20 BitNile Chevrolet for the 2022 NTT INDYCAR SERIES

Retrieved on: 
Friday, January 14, 2022 - 11:30am

20 Chevrolet in a two-year deal (subject to certain termination provisions) as Ed Carpenter Racing welcomes back Conor Daly as the full-time driver for the 2022 NTT INDYCAR SERIES season.

Key Points: 
  • 20 Chevrolet in a two-year deal (subject to certain termination provisions) as Ed Carpenter Racing welcomes back Conor Daly as the full-time driver for the 2022 NTT INDYCAR SERIES season.
  • BitNile will also serve as an associate sponsor on Ed Carpenter Racings second entry, the No.
  • View the full release here: https://www.businesswire.com/news/home/20220114005127/en/
    BitNile Holdings, Inc (NYSE American: NILE), is the primary sponsor of the Ed Carpenter Racing No.
  • 20 Chevrolet in a two-year deal as Ed Carpenter Racing welcomes back Conor Daly as the full-time driver for the 2022 NTT INDYCAR SERIES season.